AU778190B2 - Methods of inhibiting osteoclast activity - Google Patents

Methods of inhibiting osteoclast activity Download PDF

Info

Publication number
AU778190B2
AU778190B2 AU63846/00A AU6384600A AU778190B2 AU 778190 B2 AU778190 B2 AU 778190B2 AU 63846/00 A AU63846/00 A AU 63846/00A AU 6384600 A AU6384600 A AU 6384600A AU 778190 B2 AU778190 B2 AU 778190B2
Authority
AU
Australia
Prior art keywords
australia
sbmi
coms
date
received
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU63846/00A
Other languages
English (en)
Other versions
AU6384600A (en
Inventor
Mark I. Greene
Masahiko Kinosaki
Ramachandran Murali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of AU6384600A publication Critical patent/AU6384600A/en
Application granted granted Critical
Publication of AU778190B2 publication Critical patent/AU778190B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU63846/00A 1999-07-28 2000-07-28 Methods of inhibiting osteoclast activity Ceased AU778190B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14609499P 1999-07-28 1999-07-28
US60/146094 1999-07-28
PCT/US2000/020502 WO2001008677A1 (en) 1999-07-28 2000-07-28 Methods of inhibiting osteoclast activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2005200650A Division AU2005200650B2 (en) 1999-07-28 2005-02-14 Methods of inhibiting osteoclast activity

Publications (2)

Publication Number Publication Date
AU6384600A AU6384600A (en) 2001-02-19
AU778190B2 true AU778190B2 (en) 2004-11-18

Family

ID=22515834

Family Applications (2)

Application Number Title Priority Date Filing Date
AU63846/00A Ceased AU778190B2 (en) 1999-07-28 2000-07-28 Methods of inhibiting osteoclast activity
AU2005200650A Ceased AU2005200650B2 (en) 1999-07-28 2005-02-14 Methods of inhibiting osteoclast activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2005200650A Ceased AU2005200650B2 (en) 1999-07-28 2005-02-14 Methods of inhibiting osteoclast activity

Country Status (7)

Country Link
EP (1) EP1207873B1 (OSRAM)
JP (1) JP4790179B2 (OSRAM)
AT (1) ATE448781T1 (OSRAM)
AU (2) AU778190B2 (OSRAM)
CA (2) CA2380007A1 (OSRAM)
DE (1) DE60043346D1 (OSRAM)
WO (1) WO2001008677A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU777634B2 (en) * 1999-07-28 2004-10-28 Kazuhiro Aoki Methods of inhibiting osteoclastogenesis
CA2423052C (en) 2000-09-22 2011-07-12 Immunex Corporation Screening assays for agonists or antagonists of receptor activator of nf-kb
EP1401851B8 (de) 2001-07-03 2008-09-10 febit holding GmbH Zweistufige schutzgruppen für die synthese von biopolymeren
KR101560844B1 (ko) * 2007-06-04 2015-10-15 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 트라이-아릴계 화합물 및 이를 포함하는 조성물
JP5191487B2 (ja) 2007-06-05 2013-05-08 オリエンタル酵母工業株式会社 新しい骨量増加薬
CN102439026A (zh) * 2008-05-13 2012-05-02 A·R·舍拉尔 基于甾族惕告吉宁合成的苯甲酸腙的医学应用
US10000503B2 (en) 2011-09-09 2018-06-19 Sumitomo Electric Industries, Ltd. Power supply system and connector
WO2014062625A1 (en) 2012-10-15 2014-04-24 Iowa State University Research Foundation, Inc. Tackifier compounds and methods of using the same
AU2014228017B2 (en) 2013-03-15 2018-08-30 Pharmatrophix, Inc. Non-peptide BDNF Neurotrophin mimetics
JP2016516044A (ja) * 2013-03-15 2016-06-02 ファーマトロフィックス， インコーポレイテッド 非ペプチドｂｄｎｆニューロトロフィン模倣化合物
US9321803B2 (en) * 2013-07-12 2016-04-26 Children's Hospital Medical Center Compositions and methods for inhibiting norovirus infection
EA201690938A1 (ru) 2013-11-05 2016-11-30 Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания
US10077257B2 (en) 2015-04-06 2018-09-18 Iowa State University Research Foundation, Inc. Aziridinated triglycerides and polymers formed therefrom
US10392471B2 (en) 2015-05-14 2019-08-27 Iowa State University Research Foundation, Inc. Polymers and methods of making the same
WO2016186071A1 (ja) * 2015-05-20 2016-11-24 国立大学法人大阪大学 炎症性サイトカイン分泌抑制活性を有するオリゴペプチド
WO2018182983A1 (en) 2017-03-28 2018-10-04 Children's Hospital Medical Center Norovirus s particle based vaccines and methods of making and using same
CN110229118B (zh) 2019-06-28 2021-03-02 深圳市三启药物开发有限公司 腙酰胺类衍生物及其在制备抗骨质疏松药物中的应用
CN111686116B (zh) * 2020-06-08 2021-05-04 广东省微生物研究所（广东省微生物分析检测中心） 孕甾烷衍生物在制备破骨细胞分化抑制剂中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3988899A (en) * 1998-05-14 1999-11-29 Immunex Corporation Method of inhibiting osteoclast activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT951551E (pt) * 1996-12-23 2008-10-28 Immunex Corp Ligando para receptor activador de nf-kb, ligando membro da superfamília de tnf
EP2196930B1 (en) * 1998-07-01 2011-03-23 The Trustees of The University of Pennsylvania Cavity induced allosteric modificatin of intermolecular interactions and methods of identifiying compounds that effect the same
HK1040261A1 (zh) * 1998-09-15 2002-05-31 法麦克萨有限公司 负调节osteoprotegerin配体活性的方法
AU777634B2 (en) * 1999-07-28 2004-10-28 Kazuhiro Aoki Methods of inhibiting osteoclastogenesis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3988899A (en) * 1998-05-14 1999-11-29 Immunex Corporation Method of inhibiting osteoclast activity

Also Published As

Publication number Publication date
WO2001008677A1 (en) 2001-02-08
JP2003505503A (ja) 2003-02-12
JP4790179B2 (ja) 2011-10-12
AU6384600A (en) 2001-02-19
CA2380007A1 (en) 2001-02-08
AU2005200650B2 (en) 2007-11-15
EP1207873A4 (en) 2006-04-12
EP1207873A1 (en) 2002-05-29
EP1207873B1 (en) 2009-11-18
ATE448781T1 (de) 2009-12-15
AU2005200650A1 (en) 2005-03-10
CA2647796A1 (en) 2001-02-08
DE60043346D1 (de) 2009-12-31
WO2001008677A8 (en) 2001-07-12

Similar Documents

Publication Publication Date Title
US8003628B2 (en) Methods of inhibiting osteoclast activity
AU2005200650B2 (en) Methods of inhibiting osteoclast activity
EP1011704B1 (en) Tumor necrosis factor receptor-derived peptide analogues
AU2006210848B2 (en) Compositions and methods for treating fibrotic disorders
CA2272356C (en) Soluble polypeptides
AU734758B2 (en) Anti-fas antibodies
AU767912B2 (en) Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases
US6682739B1 (en) Methods of inhibiting osteoclastogenesis
AU777634B2 (en) Methods of inhibiting osteoclastogenesis
JP2014101274A (ja) 新規な架橋構造を含むｔｎｆレセプターループペプチドの模倣ペプチドを用いた医薬組成物
AU2008200757A1 (en) Methods of inhibiting osteoclast activity
PT97107A (pt) Metodo para aumentar o crescimento e proliferacao de mastocitos utilizando interleuquina-9-purificada